

09:00 – 09:30

Gallery Level and Music Foyer

Networking breakfast and partnering

Grab a #BIGIMPACT coffee and start connecting with the BIA TechBio community.

09:30 – 10:50

Hall One

Parallel workshop – When and how to think about cybersecurity as a techbio?

Cybersecurity is a growing challenge for all companies, but particularly for those in sectors like ours where IP and data make up a significant component of a company's value. However, many are relatively unprepared for the task, and as such may be vulnerable. Join this expert workshop to learn more about why you should consider cybersecurity early in your company journey, and what can be done to protect yourself moving forwards.



09:30 – 10:50

Hall Two

Parallel workshop – Level up your compensation game

We invite you to join Jody Thelander, Founder & CEO, of the namesake firm and Morgan Thelander, COO, for an in-depth session on global compensation and strategies for privately held companies across life sciences and tech. The Thelander team will share exclusive real time data, insights and analysis on all aspects of compensation, including, but not limited to:

- How cash and equity compensation in the UK and US compare and contrast
- Option pool by total amount of financing and industry
- Equity awards, what type of equity to grant, when to refresh and how that fits into your option pool

Speakers:



Jody Thelander,
Founder and CEO,
J.Thelander Consulting



Morgan Thelander,
COO,
J.Thelander Consulting

11:00 – 11:15

Hall One

Welcome and opening keynote

Come and hear from Ramesh Durvasula, Senior Vice President for R&D IT at Eli Lilly & Company, as he shares his perspective on how techbio will influence pharma and the sector.

Speakers:



Steve Bates,
CEO,
BIA



Ramesh Durvasula,
Senior Vice President, Information Officer,
R&D IT, Eli Lilly & Company



11:15 – 12:15

Hall One

Question Time: The state of TechBio in the UK

The TechBio landscape has continued to evolve rapidly in the last year. Join us as we discuss the lessons we have learned, and look ahead to what we expect to see in future. There will also be an opportunity to get answers to questions you may have about the broader picture of data driven life science in the UK.

Speakers:



Ramesh Durvasula,
Senior Vice President,
Information Officer,
R&D IT, Eli Lilly & Company



Anta Gkelou,
Partner,
Sofinnova Partners



Cassandra Padbury,
Associate Director,
Cambridge Consultants



Hakim Yadi,
CEO, Closed Loop
Medicine

The TechBio landscape has continued to evolve rapidly in the last year. Join us as we discuss the lessons we have learned, and look ahead to what we expect to see in future. There will also be an opportunity to get answers to questions you may have about the broader picture of data driven life science in the UK.

12:15 – 13:00

Investment for TechBio companies

For some, the last few months have been a time of exciting deals, while others have continued to face a challenging financial environment. In this session we will look at where the money is coming from in the second half of 2024, and how you can best set yourself up for success.

Speakers:



Chris Baker,
Investment Principal,
LifeArc



Leigh Brody,
Investment Manager,
Albion VC



Helena Fraser,
Vice President,
Life Sciences & Healthcare,
HSBC Innovation Banking



Elin Haf Davies,
CEO, Aparito



13:00 – 14:15

Gallery Level and Music Foyer

Networking lunch

Enjoy delicious food while making valuable connections with industry leaders, innovators, and potential collaborators.

#TechBioUK

14:15 – 15:00

At the cutting edge: Company showcases

Come and hear from 5 of the most exciting organisations working in this space as they walk us through their achievements, and how they will change the landscape. Vote for the one you think will have the greatest impact to give them a chance to speak again in the final plenary session.

Hall One

AI & data track

Speakers:



Simon Bornschein,
CEO & Co-Founder,
Coding Bio



Debesh Mandal,
CEO,
Nanograb



Rory Ryan,
Co-Founder & CEO,
PentaBind



Jason Yip,
CEO & Co-Founder,
Tailor Bio



Lluna Gallego,
COO & Co-Founder,
Vector Biosciences

Hall Two

Engineering biology track

Speakers:



Rebecca Godfrey,
COO,
ExpressionEdits



Adam Laing,
CEO,
IMU Biosciences



Christopher Reynolds,
Founder & CTO,
Eden Bio



James MacDonald,
CEO and Co-Founder,
Solena Materials



Zahra Jawad,
CEO & Founder,
Creasallis

St Pancras Room

Genomics track

Speakers:



Julian Gough,
Scientist and
Entrepreneur; Founder,
OutSee and Mogrify



Hazel Jones,
CEO, Enhanc3D
Genomics



David T Dexter,
Director of Research,
Parkinson's UK



**Rafael E Carazo
Salas,**
Founder and CEO,
CellVoyant



Steve Gardner,
CEO,
Precisionlife

Cooley

#TechBioUK

15:15 – 16:00

Hall One

Panel discussions

AI & data track: Spinning out vs building up – lessons from different approaches to AI companies

There are broadly two different approaches to developing thriving life science AI companies – spinning out from larger organisations, or launching as a new start-up. This session will compare the pros and cons of both approaches, and see if there’s common lessons to be learned for building a successful company. We’ll also dig into what both approaches can teach from a culture and operational perspective.

Speakers:



Aline Charpentier,
Head of Innovation,
Bruntwood SciTech



Will Kay,
Director of Product,
Isomorphic



Parker Moss,
EVP Corporate
Development,
Exscientia



Alessandro Riccombeni,
CEO,
Axia Medicine



Steve Gardner,
CEO,
Precisionlife



Noor Shaker,
Founder/CEO,
Spatialx

Hall Two

Engineering biology track: What lessons can therapeutic engineering biology teach other sectors?

Engineering biology has a long and proud history in therapeutic development, leading to a number of success stories. However, recently engineering developments outside healthcare have drawn a lot of interest, and these “deep biotech” solutions promise to help address an entirely different landscape of challenges. Join this session as we discuss what lessons these newer companies may be able to learn from their therapeutic forbears, and where their solutions must differ.

Speakers:



Kristen Albright,
CEO,
Prokarium



Sara Holland,
Partner,
Potter Clarkson LLP



Karen Polizzi,
Co-Director, Imperial
College Centre for
Synthetic Biology



Oliver Sexton,
Investment Director,
Future Planet Capital



David Venables,
CEO, Laverock
Therapeutics

St Pancras Room

Genomics track: Beyond genomics – delivering on applications of multiomics

For a number of years now, multiomic approaches have promised to revolutionise healthcare monitoring and drug discovery, and we are now entering a phase where many of these promises are starting to be delivered. Join us for a discussion of where the current state of the art is, and what remaining challenges need to be addressed for multiomics to deliver its full potential.

Speakers:



Davide Gianni,
Senior Director Functional
Genomics in Discovery
Sciences, AstraZeneca



Perman Jorayev,
Investor,
Amadeus Capital



Richard Kuo,
CEO,
Wobble Genomics



Debora Lucarelli,
CTO,
Tagomics



Leo Spicer-Phelps,
Associate, Cooley
(UK) LLP



16:00 – 16:30

Gallery Level and Music Foyer

Networking break

Recharge with a #BIGIMPACT coffee and continue conversations with the BIA TechBio community.

16:30 – 16:15

Hall One

At the cutting edge: Company showcase favourites

The audience favourite company from each track will deliver their pitch to the whole conference. Come and get a sample of what exciting developments took place in the other tracks.



Chair:
Bianca De Blasi,
Senior Data Scientist,
Citeline



17:15 – 17:30

Hall One

Closing remarks and keynote

Sergei Yakneen, Chief Technology Officer of Isomorphic Labs, will discuss how new tools are enabling a new generation of biotech solutions.

Speakers:



Steve Bates,
CEO,
BIA



Sergei Yakneen,
CTO,
Isomorphic Labs

17:30 – 20:00

Hall Two

Networking drinks reception

Join us for canapes and a glass of something cold plus lots more excellent networking.

#TechBioUK